Synopsis: Cupid Limited’s promoter and CMD, Aditya Kumar Halwasiya, purchased 21 lakh shares through the open market, increasing his stake from 33.13% to 33.29%.
This Small- Cap Pharma Stock, engaged in manufacturing and marketing male and female condoms, personal lubricants, and diagnostic products, serving healthcare and wellness markets across India and globally, jumped 2.85 percent after the promoter bought 21 lakh shares in the company
With a market capitalization of Rs. 17,810.03 crores, the share of Cupid Limited has reached an intraday high of Rs. 133.50 per equity share, rising nearly 2.85 percent from its previous day’s close price of Rs. 129.80. Since then, the stock has retreated and is currently trading at Rs. 132.45 per equity share.
Reason Behind the Surge
Cupid Limited informed the stock exchanges that its Chairman and Managing Director, Mr Aditya Kumar Halwasiya, acquired 21,00,000 equity shares of the company through an open market purchase on June 3, 2026.
Prior to the acquisition, Mr Halwasiya held 44,55,25,475 shares, representing 33.13 percent of the company’s equity share capital. Following the purchase, his shareholding increased to 44,76,25,475 shares, equivalent to 33.29 percent of the company’s equity capital.
As a result of this transaction, Mr Halwasiya’s stake increased by 21,00,000 shares, resulting in a rise of 0.16 percentage points in his shareholding. The combined holding of the promoter and promoter group increased from 61,97,24,725 shares (46.08 percent) before the acquisition to 62,18,24,725 shares (46.24 percent) after the acquisition, reflecting an overall increase of 0.16 percentage points in promoter ownership.
Management Guidance
Cupid Limited has outlined ambitious financial goals for the next three years, targeting revenue of Rs. 600 crore in FY27, Rs. 875 crore in FY28, and Rs. 1,150 crore in FY29. The company also expects net profit to rise to Rs. 180 crore, Rs. 275 crore, and Rs. 390 crore during the same period. These targets imply a revenue CAGR of up to 48 percent and a net profit CAGR of up to 53 percent by FY29, reflecting management’s confidence in the company’s growth strategy and market opportunities.
Expansion Plans
Cupid Limited plans to achieve its growth targets by rapidly expanding its FMCG distribution network across India and increasing the contribution of its high-margin B2C business.
In addition, Cupid is focusing on growing exports, expanding manufacturing capacity for male and female condoms, and launching new products in the lubricants, wellness, and diagnostics segments. Improved operational efficiencies, economies of scale, and benefits from backward integration are also expected to support profitability and long-term growth.
Company Overview
Cupid Limited is a healthcare and wellness products company based in Nashik, Maharashtra, with operations spanning both domestic and international markets. Founded in 1993, the company manufactures a range of products, including male and female condoms, personal lubricants, and in vitro diagnostic (IVD) kits, serving healthcare and consumer needs across multiple regions.
The company has built a strong reputation for quality and innovation in reproductive healthcare. It was among the earliest manufacturers to receive prequalification from leading international organizations such as the World Health Organization (WHO) and the United Nations Population Fund (UNFPA) for both male and female condoms, highlighting its adherence to globally recognized quality standards.
Recent Quarter Results
Coming into financial highlights, Cupid Limited’s revenue has increased from Rs. 61 crore in Q4 FY25 to Rs. 132 crore in Q4 FY26, which has grown by 116.39 percent. The net profit has also grown by 200 percent from Rs. 12 crore in Q4 FY25 to Rs. 36 crore in Q4 FY26.
Cupid Limited’s revenue and net profit have grown at a CAGR of 34.98 percent and 50 percent, respectively, over the last three years. In terms of return ratios, the company’s ROCE and ROE stand at 33.5 percent and 27.3 percent, respectively. Cupid Limited has an earnings per share (EPS) of Rs. 0.81, and its debt-to-equity ratio is 0.13x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
